174 related articles for article (PubMed ID: 23843173)
1. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Int J Cancer; 2014 Jan; 134(2):478-86. PubMed ID: 23843173
[TBL] [Abstract][Full Text] [Related]
2. Mucolysis by ascorbic acid and hydrogen peroxide on compact mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
J Surg Res; 2012 May; 174(2):e69-73. PubMed ID: 22261589
[TBL] [Abstract][Full Text] [Related]
3. Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer.
Dilly AK; Honick BD; Frederick R; Elapavaluru A; Velankar S; Makala H; Hitchens TK; Foley LM; Guo J; Beumer JH; Rigatti LH; Lee YJ; Bartlett DL; Choudry HA
Transl Res; 2021 Mar; 229():100-114. PubMed ID: 33164812
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of bromelain and acetylcysteine in pseudomyxoma peritonei (PMP) caused by low-grade appendiceal mucinous neoplasm (LAMN): a case report.
Geisel D; Langen U; Rüdiger T
J Med Case Rep; 2023 Jun; 17(1):297. PubMed ID: 37381056
[TBL] [Abstract][Full Text] [Related]
5. Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP).
Pillai K; Akhter J; Mekkawy A; Chua TC; Morris DL
Int J Med Sci; 2017; 14(1):18-28. PubMed ID: 28138305
[No Abstract] [Full Text] [Related]
6. In vivo model of pseudomyxoma peritonei for novel candidate drug discovery.
Chua TC; Akther J; Yao P; Morris DL
Anticancer Res; 2009 Oct; 29(10):4051-5. PubMed ID: 19846950
[TBL] [Abstract][Full Text] [Related]
7. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
8. Depletion of mucin in mucin-producing human gastrointestinal carcinoma: Results from in vitro and in vivo studies with bromelain and N-acetylcysteine.
Amini A; Masoumi-Moghaddam S; Ehteda A; Liauw W; Morris DL
Oncotarget; 2015 Oct; 6(32):33329-44. PubMed ID: 26436698
[TBL] [Abstract][Full Text] [Related]
9. Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Invest New Drugs; 2012 Oct; 30(5):2080-6. PubMed ID: 22359216
[TBL] [Abstract][Full Text] [Related]
10. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
Choudry HA; Mavanur A; O'Malley ME; Zeh HJ; Guo Z; Bartlett DL
Ann Surg Oncol; 2012 May; 19(5):1402-9. PubMed ID: 22302271
[TBL] [Abstract][Full Text] [Related]
11. Mucin as a therapeutic target in pseudomyxoma peritonei.
Choudry HA; O'Malley ME; Guo ZS; Zeh HJ; Bartlett DL
J Surg Oncol; 2012 Dec; 106(7):911-7. PubMed ID: 22585683
[TBL] [Abstract][Full Text] [Related]
12. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.
Gilbreath JJ; Semino-Mora C; Friedline CJ; Liu H; Bodi KL; McAvoy TJ; Francis J; Nieroda C; Sardi A; Dubois A; Lazinski DW; Camilli A; Testerman TL; Merrell DS
Orphanet J Rare Dis; 2013 Jul; 8():105. PubMed ID: 23844722
[TBL] [Abstract][Full Text] [Related]
13. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
14. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.
Amini A; Masoumi-Moghaddam S; Ehteda A; Morris DL
Orphanet J Rare Dis; 2014 May; 9():71. PubMed ID: 24886459
[TBL] [Abstract][Full Text] [Related]
15. Transhepatic Bromelain and Acetylcysteine for Treatment of Posterior Gastric Pseudomyxoma Peritonei: A Case Report.
Sun SL; Sarofim M; Morris DL
Anticancer Res; 2024 May; 44(5):2239-2241. PubMed ID: 38677761
[TBL] [Abstract][Full Text] [Related]
16. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic evacuation of mucinous ascites for palliation of pseudomyxoma peritonei.
Kelly KJ; Baumgartner JM; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1722-5. PubMed ID: 25395145
[TBL] [Abstract][Full Text] [Related]
18. Experimental models and questions in basic science research for pseudomyxoma peritonei.
Lambert LA; Lambert DH; Mansfield P
Recent Results Cancer Res; 2007; 169():105-14. PubMed ID: 17506254
[No Abstract] [Full Text] [Related]
19. [Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
Smeenk RM; Verwaal VJ; Zoetmulder FA
Ned Tijdschr Geneeskd; 2007 Feb; 151(7):418-23. PubMed ID: 17343142
[TBL] [Abstract][Full Text] [Related]
20. MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study.
Mall AS; Chirwa N; Govender D; Lotz Z; Tyler M; Rodrigues J; Kahn D; Goldberg P
Pathol Int; 2007 Aug; 57(8):537-47. PubMed ID: 17610480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
